The Regulation of Nicotine in the United Kingdom: How Nicotine Gum Came to Be a Medicine, But Not a Drug
The Regulation of Nicotine in the United Kingdom: How Nicotine Gum Came to Be a Medicine, But Not a Drug
复制标题
英国对尼古丁的监管：尼古丁口香糖如何成为一种药物，而不是一种药物
DOI：
10.1111/j.1467-6478.2012.00569.x
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
R. Dingwall
中科院分区：
文献类型：
--
作者：
Catriona Rooke;E. Cloatre;R. Dingwall
本文探讨了行动者网络理论（ANT）作为社会法律研究工具的效用。ANT被部署在英国烟草和药用尼古丁（MN）产品的监管责任划分的演变研究中，特别关注后者如何作为一种药物进行监管。我们研究了英国对第一种MN产品的监管决定：瑞典开发的含尼古丁的口香糖，1980年根据1968年《药品法》作为处方药在英国上市。我们建议，利用ANT来探索尼古丁口香糖的发展和对它采取的监管决定，将这些决定置于烟草控制和成瘾的更广泛的背景下，并帮助我们更好地了解不同的物质参与者如何在不同的网络中发挥作用，从而导致非常不同的监管系统。
This article explores the utility of actor-network theory (ANT) as a tool for socio-legal research. ANT is deployed in a study of the evolution of divided regulatory responsibility for tobacco and medicinal nicotine (MN) products in the United Kingdom, with a particular focus on how the latter came to be regulated as a medicine. We examine the regulatory decisions taken in the United Kingdom in respect of the first MN product: a nicotine-containing gum developed in Sweden, which became available in the United Kingdom in 1980 as a prescription-only medicine under the Medicines Act 1968. We propose that utilizing ANT to explore the development of nicotine gum and the regulatory decisions taken about it places these decisions into the wider context of ideas about tobacco control and addiction, and helps us to understand better how different material actors acted in different networks, leading to very different systems of regulation.